A Randomized, Open-label, 3-way Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects

Trial Profile

A Randomized, Open-label, 3-way Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2014

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Epilepsy; Fibromyalgia; Generalised anxiety disorder; Neuropathic pain; Postherpetic neuralgia
  • Focus Pharmacokinetics
  • Acronyms GLA5PR-101
  • Sponsors GL PharmTech
  • Most Recent Events

    • 01 Nov 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top